A recommended first-line therapy option for HER2-positive ABC is the combination of pertuzumab, trastuzumab, and docetaxel which was observed to improve progression free survival (PFS) and overall survival (OS) compared to trastuzumab and docetaxel in the CLEOPATRA study (1–4). This evidence concerns the gene ERBB2 and aneurysmal bone cyst.